Search Medical Condition
Please enter condition
Please choose location from dropdown

Lankenau Medical Center, Pennsylvania Clinical Trials

A listing of Lankenau Medical Center, Pennsylvania clinical trials actively recruiting patient volunteers.

RESULTS

Found (1990) clinical trials

Transcatheter Mitral Valve Replacement With the Medtronic Intrepid TMVR System in Patients With Severe Symptomatic Mitral Regurgitation

Multi-center, global, prospective, randomized, interventional, pre-market trial with two subject groups: the randomized group will be randomized on 1:1 basis to either the study device or to conventional mitral valve surgery. Subjects in the single-arm group will receive the study device. Subjects will be seen at pre- and post-procedure, discharge, ...

Phase N/A

0.8 miles

Learn More »

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

PRIMARY OBJECTIVES: I. Measure the ability of two dose levels of bupropion hydrochloride (bupropion), 150 or 300 mg of extended release, to improve sexual desire more than a placebo at 9 weeks (8 weeks on the target dose) as measured by the desire subscale of the female sexual function index ...

Phase

0.8 miles

Learn More »

Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian Fallopian Tube or Primary Peritoneal Cancer

PRIMARY OBJECTIVES: I. To assess the efficacy and identify (in)active arm(s) of the combination of cediranib maleate (cediranib) and olaparib, cediranib alone, olaparib alone, and physician's choice standard of care chemotherapy, as measured by progression-free survival (PFS) in the setting of recurrent platinum-resistant or-refractory ovarian, primary peritoneal or fallopian tube ...

Phase

0.8 miles

Learn More »

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

PRIMARY OBJECTIVE: I. To evaluate whether therapy with nivolumab following combined modality therapy (CMT) improves disease-free survival (DFS) compared with observation in patients with high risk anal carcinoma. SECONDARY OBJECTIVES: I. To compare nivolumab following combined modality therapy (CMT) with observation in patients with high risk anal carcinoma with regard ...

Phase

0.8 miles

Learn More »

Sentus QP - Extended CRT Evaluation With Quadripolar Left Ventricular Leads

The QP ExCELs study is designed to confirm safety and efficacy of the BIOTRONIK Sentus OTW QP left ventricular leads to satisfy FDA requirements for regulatory approval of the leads in the US. The Sentus OTW QP leads received FDA approval on May 4, 2017. Long-term safety of the BIOTRONIK ...

Phase N/A

0.97 miles

Learn More »

Product Surveillance Registry

The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies, payers, and industry by streamlining the clinical surveillance process and facilitating leading edge ...

Phase N/A

0.97 miles

Learn More »

Radiographic Imaging Validation and EvALuation for Angio iFR (ReVEAL iFR)

This study is intended to demonstrate the diagnostic performance of the image-derived physiology model using the invasive physiological measures as the reference standard. Specific objectives include the following: i) Demonstrate the diagnostic accuracy of image-derived iFR and FFR results for identifying functionally significant lesions as determined by the corresponding invasive ...

Phase N/A

0.97 miles

Learn More »

Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

All Medtronic market-released leads and all market-released IPG, ICD and CRT devices are eligible to be included in this study.

Phase N/A

1.09 miles

Learn More »

Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

OBJECTIVES Primary To determine if administering adjuvant systemic chemotherapy after chemoradiotherapy will improve disease-free survival compared to chemoradiotherapy alone in patients with high-risk early-stage cervical carcinoma found to have positive nodes and/or positive parametria after radical hysterectomy. Secondary To evaluate adverse events. To evaluate overall survival. To evaluate quality of ...

Phase

1.09 miles

Learn More »

Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer

The prescribed PTV dose of 36.25Gy shall be given in 5 fractions using the Truebeam STx. At one week after treatment, toxicity and AUA score will be evaluated. At 1 month following treatment, patients will be assessed for acute toxicity, and will fill out AUA form, SF-12, EPIC-26, SHIM and ...

Phase

1.09 miles

Learn More »